Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Fludarabine-Resistant CLL and Related Disorders
NCT00413478Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2006
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in chronic lymphocytic leukemia (CLL), Richter's transformation (RT), T-cell prolymphocytic leukemia (T-PLL), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2006; status: terminated.
02
Drugs
azacitidine
03
Conditions
chronic lymphocytic leukemia (CLL)Richter's transformation (RT)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT00413478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413478.